Novel treatments for cardiovascular disease prevention

Cardiovascular Therapeutics

Volumn 30, Issue 5, 2012, Pages 257-263

  Huffman, Mark D ^a   Bhatnagar, Deepak ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cardiovascular disease; Novel; Prevention; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMFEBUTAMONE; ANACETRAPIB; APIXABAN; ARGATROBAN; AVASIMIBE; CANGRELOR; CLOPIDOGREL; DABIGATRAN; DALCETRAPIB; DARAPLADIB; DIPYRIDAMOLE; HEPARIN; HIRUDIN; HIRULOG; LOMITAPIDE; MIPOMERSEN; NICOTINIC ACID; PACTIMIBE; PITAVASTATIN; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; TORCETRAPIB; UNINDEXED DRUG; VARENICLINE; VARESPLADIB; WARFARIN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BEHAVIOR CHANGE; BIOASSAY; BLEEDING; BLOOD PRESSURE; BRAIN ISCHEMIA; CALORIC RESTRICTION; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EQUIPMENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; COMMUNITY PROGRAM; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY RECANALIZATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DYSLIPIDEMIA; EPIDEMIC; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH PROGRAM; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INJECTION SITE ERYTHEMA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; MOOD CHANGE; MORBIDITY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; SMOKING CESSATION PROGRAM; STENT THROMBOSIS; STROKE; THROMBOCYTE FUNCTION; THROMBOSIS; TOBACCO DEPENDENCE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; ATRIAL APPENDAGE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; CLINICAL LABORATORY TECHNIQUES; COMMUNITY HEALTH SERVICES; FIBRINOLYTIC AGENTS; HUMANS; HYPOLIPIDEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; SMOKING CESSATION;

EID: 84866009264     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00280.x     Document Type: Review

References (54)

1. World Health Organization. Disease and injury regional estimates for 2004, Geneva, Switzerland. Available from: http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html [Accessed 5 September 2009.
2. Mirzaei M, Truswell AS, Taylor R, Leeder SR. Coronary heart disease epidemics: Not all the same. Heart 2009;95:740-746.
3. United States Food and Drug Administration. 2006. FDA approves novel medication for smoking cessation. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108651.htm [Accessed 10 June 2010.
4. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006;296:47-55.
5. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010;121:221-229.
6. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-1568.
7. United Staes Food and Drug Administration. Postmarket drug safety information for healthcare professionals: Varenicline (marketed as Chantix). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm [Accessed 10 June 2010.
8. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
9. Unger EF. Weighing benefits and risks-the FDA's review of prasugrel. N Engl J Med 2009;361:942-945.
10. Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009;361:940-942.
11. United States Food and Drug Administration. 2010. Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220197.pdf [Accessed 5 August 2010.
12. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-2329.
13. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-2341.
14. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: Current and future advances. Circulation 2007;116:552-560.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
16. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet 2009;374:29-38.
17. ROCKET AF study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. Am Heart J 2010;159:340-347.e1.
18. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009;54:293-302.
19. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-1735.
20. Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010;55:1611-1618.
21. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006.
22. Robinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vasc Health Risk Manag 2009;5:31-43.
23. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-2415.
24. Baxter JD, Webb P. Thyroid hormone mimetics: Potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009;8:308-320.
25. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805.
26. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010;9:141-153.
27. Suckling K. Phospholipase A2s: Developing drug targets for atherosclerosis. Atherosclerosis 2010;212:357-366.
28. Wilensky RL, Shi Y, Mohler ER, 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-1066.
29. United States Food and Drug Administration. 2007. Drug approval package. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021985s000TOC.cfm [Accessed 4 August 2010.
30. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens 2007;1:264-277.
31. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-537.
32. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
33. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
34. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009;374:534-542.
35. United States Food and Drug Administration. 2009. Circulatory system devices panel April 23, 2009 meeting. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/ucm152596.htm [Accessed 4 August 2010.
36. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A 2004;101:6659-6663.
37. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007;120:713-719.
38. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
39. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): A phase II, double-blind, randomised trial. Lancet 2009;373:1341-1351.
40. Fahey T, Brindle P, Ebrahim S. The polypill and cardiovascular disease. BMJ 2005;330:1035-1036.
41. Reddy KS. The preventive polypill-much promise, insufficient evidence. N Engl J Med 2007;356:212.
42. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: Rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009;6:101-110.
43. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832.
44. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762.
45. Price MJ, Berger PB, Angiolillo DJ, et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. Am Heart J 2009;157:818-824, 824.e1.
46. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) design. Available from: http://clinicaltrials.gov/ct2/show/NCT00910299 [Accessed 5 August 2010.
47. Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC). Available from: http://clinicaltrials.gov/ct2/show/NCT00827411?term=ARCTIC&rank=1 [Accessed 5 August 2010.
48. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R, Sr., O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-97.
49. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
50. FDA Approves New Indication for Crestor. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200128.htm [Accessed 5 August 2010.
51. Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER?Arch Intern Med 2010;170:1073-1077.
52. Ebrahim S, Smith GD. Exporting failure? Coronary heart disease and stroke in developing countries. Int J Epidemiol 2001;30:201-205.
53. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011: CD001561.
54. Prabhakaran D, Jeemon P, Goenka S, et al. Impact of a worksite intervention program on cardiovascular risk factors: A demonstration project in an Indian industrial population. J Am Coll Cardiol 2009;53:1718-1728.